IPD - L-Dex® granted reimbursement status for all cancer related lymphoedema
HIGHLIGHTS
Transformational event for ImpediMed, reimbursement status for use of L-Dex across all relevant cancer types
Expands L-Dex addressable market opportunity to over US$ 350 million per annum
- Forums
- ASX - Short Term Trading
- STT Thread Week Starting 1st Sept.